Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.880
-0.020 (-2.24%)
At close: Dec 5, 2025, 4:00 PM EST
0.895
+0.015 (1.75%)
After-hours: Dec 5, 2025, 7:59 PM EST
Femasys Revenue
Femasys had revenue of $729.39K in the quarter ending September 30, 2025, with 31.44% growth. This brings the company's revenue in the last twelve months to $2.06M, up 63.53% year-over-year. In the year 2024, Femasys had annual revenue of $1.63M with 51.97% growth.
Revenue (ttm)
$2.06M
Revenue Growth
+63.53%
P/S Ratio
12.60
Revenue / Employee
$29,035
Employees
71
Market Cap
51.36M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FEMY News
- 10 days ago - PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Business Wire
- 4 weeks ago - Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million - GlobeNewsWire
- 7 weeks ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire
- 3 months ago - Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed® - GlobeNewsWire
- 3 months ago - Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand - GlobeNewsWire
- 3 months ago - Femasys Announces Pricing of $8.0 Million Underwritten Public Offering - GlobeNewsWire
- 4 months ago - Femasys Revenue Jumps 85 Percent in Q2 - The Motley Fool
- 4 months ago - Femasys Announces Second Quarter Financial Results for 2025 - GlobeNewsWire